2-(2-pyridyl)-1,3-dithiane | 80085-67-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二噻烷
• 英文名称: 2-(2-pyridyl)-1,3-dithiane
• 英文别名: 2-(2-Pyridyl)-1,3-dithian；2-(1,3-Dithian-2-yl)pyridine
• CAS: 80085-67-2
• 化学式: C₉H₁₁NS₂
• 分子量: 197.325
• InChiKey: TXPFNZZSEXQEDY-UHFFFAOYSA-N

物化性质

• 沸点：
  354.0±42.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  63.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-pyridyl)-1,3-dithiane 在 正丁基锂 、 氨 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 2-(pyrid-2-yl)-1,3-dithiane-2-carbothioamide
  参考文献：
  名称：

  Synthesis and antisecretory and antiulcer activities of derivatives and analogs of 2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide

  摘要：

  New thioamide derivatives of 2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide (29) and related compounds (in which the tetrahydrothiophene ring was replaced by tetrahydrothiopyran, tetrahydrofuran, 1,3-dithiane, or 1,3-oxathiane and where the pyridine ring was replaced by other nitrogen heterocycles) were synthesized and tested for their antisecretory and antiulcer activities. These thioamides were prepared according to one of the following methods: reaction of an isothiocyanate with the carbanion of the corresponding cyclic precursor (for secondary thioamides); reaction of ammonia or an amine with the dithio ester prepared from the same precursor (for primary, secondary, and tertiary thioamides). These thioamides were evaluated by the Shay method to measure their antisecretory activity and by the stress-induced-ulcer method to test their antiulcer activity. Structure-activity relationships are discussed. N-Methyl-2-(2-pyridyl)tetrahydrothiophene-2-carbothioamide (R.P. 40749, 30) exhibited activities that were at least 10 times higher than those reported for cimetidine.

  DOI：

  10.1021/jm00384a004
• 作为产物：
  描述：

  吡啶-2-甲醛 、 1,3-丙二硫醇 在 对甲苯磺酸 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以54%的产率得到2-(2-pyridyl)-1,3-dithiane
  参考文献：
  名称：

  Pot-Economy Autooxidative Condensation of 2-Aryl-2-lithio-1,3-dithianes

  摘要：

  The autoxidative condensation of 2-aryl-2-lithio-1,3-dithianes is here reported. Treatment of 2-aryl-1,3-dithianes with n-BuLi in the absence of any electrophile leads to condensation of three molecules of 1,3-dithianes and formation of highly functionalized α-thioether ketones orthothioesters in 51-89% yields upon air exposure. The method was further expanded to benzaldehyde dithioacetals, affording corresponding orthothioesters and α-thioether ketones in 48-97% yields. The experimental results combined with density functional theory studies support a mechanism triggered by the autoxidation of 2-aryl-2-lithio-1,3-dithianes to yield a highly reactive thioester that undergoes condensation with two other molecules of 2-aryl-2-lithio-1,3-dithiane.

  DOI：

  10.1021/acs.joc.7b02896

文献信息

• Dimeric Potassium Amide-Catalyzed α-Alkylation of Benzyl Sulfides and 1,3-Dithianes
  作者：Yu-Feng Liu、Lei Zheng、Dan-Dan Zhai、Xiang-Yu Zhang、Bing-Tao Guan

  DOI：10.1021/acs.orglett.9b01994

  日期：2019.7.5

  The first catalytic α-alkylation reaction of benzyl sulfides and 1,3-dithianes with styrenes and conjugated dienes was developed under mild conditions by using a readily available Brønsted base potassium bis(trimethylsilyl)amide (KHMDS) as catalyst. The reaction displayed good functional group tolerance, high efficiency, and excellent chemoselectivity. A series of desired alkylation products were obtained

  苄基硫醚和1,3-二硫杂环丁烷与苯乙烯和共轭二烯的第一个催化α-烷基化反应是在温和条件下通过使用容易获得的布朗斯台德双（三甲基甲硅烷基）酰胺基钾（KHMDS）催化剂开发的。该反应显示出良好的官能团耐受性，高效率和优异的化学选择性。以良好或高收率获得了一系列所需的烷基化产物。初步的机理研究表明，两个酰胺化钾催化剂分子在催化循环中共同起作用。
• Tetrazole derivatives, and anti-ulcer composition containing the same
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：US04372953A1

  公开（公告）日：1983-02-08

  Tetrazole derivatives of the formula: ##STR1## wherein R.sup.1 is a lower alkykl, phenyl or a group of the formula: --S(O).sub.l --A--(X).sub.m --R.sup.3, and R.sup.2 is hydrogen, a lower alkyl, phenyl or a cycloalkyl when R.sup.1 is the group --S(O).sub.l --A--(X).sub.m --R.sup.3, or R.sup.2 is a group of the formula: --B--CO--R.sup.4 when R.sup.1 is a lower alkyl or phenyl and a pharmaceutically acceptable salt thereof, which have prophylactic or therapeutic activities against peptic and/or duodenal ulcers and are useful as an anti-ulcer drug; processes for the preparation of the tetrazole derivatives; and pharmaceutical composition containing said tetrazole derivatives.

  Tetrazole衍生物的化学式为：##STR1## 其中R.sup.1是较低的烷基、苯基或化学式的基团：--S(O).sub.l --A--(X).sub.m --R.sup.3，而R.sup.2是氢、较低的烷基、苯基或环烷基，当R.sup.1是基团--S(O).sub.l --A--(X).sub.m --R.sup.3时，或者R.sup.2是化学式的基团：--B--CO--R.sup.4，当R.sup.1是较低的烷基或苯基时，以及其药学上可接受的盐，具有预防或治疗胃溃疡和/或十二指肠溃疡的活性，并可用作抗溃疡药物；制备Tetrazole衍生物的方法；以及含有上述Tetrazole衍生物的药物组合物。
• Battling Glioblastoma: A Novel Tyrosine Kinase Inhibitor with Multi-Dimensional Anti-Tumor Effect
  作者：Anisha Viswanathan、Aliyu Musa、Akshaya Murugesan、João Vale、Carlos Afonso、Saravanan Konda Mani、Olli Yli-Harja、Nuno Candeias、Meenakshisundaram Kandhavelu

  DOI：10.3390/cells8121624

  日期：——

  Glioblastoma (GB), a grade IV glioma, with high heterogeneity and chemoresistance, obligates a multidimensional antagonist to debilitate its competence. Considering the previous reports on thioesters as antitumor compounds, this paper investigates on use of this densely functionalized sulphur rich molecule as a potent anti-GB agent. Bio-evaluation of 12 novel compounds, containing α-thioether ketone and orthothioester functionalities, identified that five analogs exhibited better cytotoxic profile compared to standard drug cisplatin. Detailed toxicity studies of top compound were evaluated in two cell lines, using cell viability test, apoptotic activity, oxidative stress and caspase activation and RNA-sequencing analysis, to obtain a comprehensive molecular profile of drug activity. The most effective molecule presented half maximal inhibitory concentration (IC50) values of 27 μM and 23 μM against U87 and LN229 GB cells, respectively. Same compound effectively weakened various angiogenic pathways, mainly MAPK and JAK-STAT pathways, downregulating VEGF. Transcriptome analysis identified significant promotion of apoptotic genes, and genes involved in cell cycle arrest, with concurrent inhibition of various tyrosine kinase cascades and stress response genes. Docking and immunoblotting studies suggest EGFR as a strong target of the orthothioester identified. Therefore, orthothioesters can potentially serve as a multi-dimensional chemotherapeutic possessing strong cytotoxic, anti-angiogenic and chemo-sensitization activity, challenging glioblastoma pathogenesis.

  胶质母细胞瘤（GB），一种高度异质性和化疗抵抗性的四级胶质瘤，需要多维对抗剂来削弱其竞争力。考虑到之前关于硫酯类化合物作为抗肿瘤化合物的报告，本文调查了这种功能丰富的硫含量丰富的分子作为一种有效的抗GB剂的用途。对包含α-硫醚酮和正硫酯功能的12种新化合物进行生物评价，发现其中五种类似物相比标准药物顺铂表现出更好的细胞毒性特征。对最佳化合物的详细毒性研究在两种细胞系中进行了评估，使用细胞存活率测试、凋亡活性、氧化应激和caspase激活以及RNA测序分析，以获得药物活性的全面分子特征。最有效的分子在U87和LN229 GB细胞中的半数最大抑制浓度（IC50）值分别为27μM和23μM。相同的化合物有效地削弱了各种血管生成途径，主要是MAPK和JAK-STAT途径，降低了VEGF的表达。转录组分析确定了凋亡基因的显着促进，以及参与细胞周期阻滞的基因，同时抑制了各种酪氨酸激酶级联和应激反应基因。对接和免疫印迹研究表明EGFR是正硫酯酯的一个强大靶点。因此，正硫酯酯有望作为一种具有强烈细胞毒性、抗血管生成和化疗敏感性活性的多维化疗药物，挑战胶质母细胞瘤的发病机制。
• Thiocarboxamide derivatives and their use as pharmaceuticals
  申请人：Rhone-Poulenc Sante

  公开号：US04379154A1

  公开（公告）日：1983-04-05

  Thioformamide derivatives of the formula: ##STR1## wherein R represents hydrogen or alkyl of 1 through 4 carbon atoms, and (i) Het represents a heterocyclic radical selected from pyrid-3-yl, pyrid-4-yl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolyl, imidazolyl, naphthyridinyl, quinoxalinyl and quinazolinyl, X represents sulphur or oxygen and Y represents sulphur or oxygen, a valency bond or methylene, or (ii) Het represents pyrid-2-yl, X represents sulphur or oxygen and Y represents sulphur or oxygen or methylene, or (iii) Het represents pyrid-2-yl, X represents oxygen and Y represents a valency bond, are new compounds possessing useful pharmacological properties. They are particularly useful in the treatment of gastrointestinal ulcers and in the treatment of hypertension, depending on the definition of the symbol Het.

  式为：##STR1## 其中R代表氢或1至4个碳原子的烷基，(i)Het代表从吡啶-3-基、吡啶-4-基、吡嗪基、吡咯嗪基、嘧啶基、喹啉基、咪唑基、萘啶基、喹喔啉基和喹唑啉基中选出的杂环基，X代表硫或氧，Y代表硫或氧、一个价键或亚甲基，或者(ii) Het代表吡啶-2-基，X代表硫或氧，Y代表硫或氧或亚甲基，或者(iii) Het代表吡啶-2-基，X代表氧，Y代表一个价键的新化合物具有有用的药理学性质。它们在治疗胃肠溃疡和高血压方面特别有用，具体取决于符号Het的定义。
• Prolylcarboxypeptidase inhibitors
  申请人：Debenham John S.

  公开号：US09006268B2

  公开（公告）日：2015-04-14

  Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

  结构式I的化合物是脯氨酰羧肽酶（PrCP）的抑制剂。本发明的化合物可用于预防和治疗与PrCP酶活性相关的疾病，如异常代谢，包括肥胖症；糖尿病；代谢综合征；与肥胖有关的疾病；以及与糖尿病有关的疾病。